tradingkey.logo

enVVeno Medical Corp

NVNO

4.880USD

+0.010+0.21%
Horário de mercado ETCotações atrasadas em 15 min
93.93MValor de mercado
PerdaP/L TTM

enVVeno Medical Corp

4.880

+0.010+0.21%
Mais detalhes de enVVeno Medical Corp Empresa
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.
Informações da empresa
Código da empresaNVNO
Nome da EmpresaenVVeno Medical Corp
Data de listagemMay 31, 2018
CEOMr. Robert A. Berman
Número de funcionários37
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 31
Endereço70 Doppler
CidadeIRVINE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92618
Telefone19492612900
Sitehttps://envveno.com/
Código da empresaNVNO
Data de listagemMay 31, 2018
CEOMr. Robert A. Berman
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
102.34K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
10.36K
-7.17%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Investidores
Investidores
Proporção
Kingdon Capital Management, L.L.C.
4.46%
The Vanguard Group, Inc.
3.12%
Nantahala Capital Management, LLC
3.09%
UBS O'Connor LLC
1.54%
Westside Investment Management, LLC
1.35%
Other
86.44%
Tipos de investidores
Investidores
Proporção
Hedge Fund
10.14%
Investment Advisor
6.99%
Investment Advisor/Hedge Fund
2.62%
Research Firm
1.20%
Individual Investor
0.92%
Venture Capital
0.17%
Private Equity
0.14%
Other
77.80%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
72
3.82M
21.80%
-3.16M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
2023Q1
54
2.76M
29.13%
-1.37M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Kingdon Capital Management, L.L.C.
859.26K
4.9%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
600.91K
3.43%
+11.77K
+2.00%
Mar 31, 2025
Nantahala Capital Management, LLC
594.66K
3.39%
-2.26K
-0.38%
Mar 31, 2025
UBS O'Connor LLC
296.03K
1.69%
--
--
Mar 31, 2025
Westside Investment Management, LLC
259.05K
1.48%
+54.02K
+26.35%
Mar 31, 2025
Geode Capital Management, L.L.C.
197.30K
1.13%
+15.56K
+8.56%
Mar 31, 2025
J.P. Morgan Securities LLC
194.21K
1.11%
-75.83K
-28.08%
Mar 31, 2025
Altium Capital Management LP
123.26K
0.7%
-186.74K
-60.24%
Mar 31, 2025
Duhay (Francis)
102.34K
0.58%
--
--
Feb 26, 2025
Dauntless Investment Group, LLC
70.85K
0.4%
+70.85K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proporção0.02%
Dimensional US Core Equity 1 ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Data
Tipo
Proporção
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
Nov 27, 2020
Merger
25<1
KeyAI